Prescription Drug Advertising to Consumers Expands in 1994

In 1994, the pharmaceutical industry expanded its marketing efforts to directly target consumers, with a 42 percent increase in prescription product advertising between January and September. This shift in focus is attributed to the growing awareness of personal health among the public. Companies are advertising their medications to inform consumers about their products and encourage them to discuss them with their physicians. Much of this advertising is focused on treating symptomatic benign prostatic hyperplasia, with popular medications like Hytrin by Abbott Laboratories and Proscar by Merck & Company being prominently featured in print media.

Key Takeaways:

• Prescription product advertising to consumers increased by 42 percent in the first nine months of 1994, totaling $187.4 million, according to Competitive Media Reporting.
• The pharmaceutical industry spent a total of $10 billion annually on promotional activities, with only a small fraction dedicated to direct-to-consumer advertising.
• Increased receptivity among consumers to information about their personal health care has led to more companies advertising directly to the public.
• Most direct-to-consumer advertising is focused on treating symptomatic benign prostatic hyperplasia, with popular medications like Hytrin and Proscar being widely advertised.
• The Federal Government requires extensive data from pharmaceutical companies in their advertising, with the Food and Drug Administration regulating the industry.
• To prevent violations, the Government encourages drug companies to have their consumer ads reviewed before publication.
• Consumer ads usually take three forms: health-seeking, reminder, and those mentioning the brand and usage.
• Advertisers must provide a brief summary of prescribing information and potential side effects in print ads.
• Waiting-room research is used to evaluate the effectiveness of ads, with some reaching up to 33 percent of the target population.

Statistics:

• $187.4 million: The total amount spent on direct-to-consumer prescription product advertising in the first nine months of 1994.
• 42 percent: The increase in direct-to-consumer prescription product advertising between January and September 1994.
• $10 billion: The total amount spent annually by the pharmaceutical industry on promotional activities.
• $48.2 million: The amount spent on nonprofessional advertising in 1990, compared to $187.4 million in 1994.
• 33 percent: The maximum percentage of the target population reached by some ads in waiting-room research.
• 5 percent: The minimum percentage of the target population reached by some ads in waiting-room research.

Sources:

• Competitive Media Reporting (1994). "Direct-to-Consumer Prescription Product Advertising Reaches $187.4 Million."
• Perq Research Corporation (cited in the article).
• Abbott Laboratories (cited in the article).
• Merck & Company (cited in the article).
• Food and Drug Administration (cited in the article).
• Medicus Consumer/D.M.B.& B. (cited in the article).
• Rubin-Ehrenthal & Associates (cited in the article).